Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I TH-302 with preoperative chemoradiotherapy for distal esophageal or esophagogastric junction adenocarcinoma
NL-OMON41947Phase 1Withdrawn
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evofosfamide in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Dose-limiting toxicity and determination of MTD/RP2D. Planned start Jul 2015; status: withdrawn.
02
Drugs
evofosfamide
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON41947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41947.